Head-to-head evidence
Divozilimab vs Ofatumumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: CD20 · full Multiple Sclerosis pipeline
Divozilimab
Developed by Biocad
NCT06987851 · Phase 3 · completed
This was an open-label, single-group extension study without a comparator, enrolling 44 participants who continued from the prior BCD-132-4/MIRANTIBUS study after earlier BCD-132 treatment. Its primary endpoint was the clinical measure of annualized relapse rate at 48 and 96 weeks, but the result was not reported.
Ofatumumab
Marketed by Novartis and partners
NCT02792231 · Phase 3 · completed
This was a large, randomized, quadruple-blind, active-controlled trial of 955 participants, comparing ofatumumab with teriflunomide. The prespecified primary clinical endpoint, annualized confirmed relapse rate, was significantly better with ofatumumab (p<0.001), supporting a strong evidence grade despite mixed findings for some secondary measures.
Next expected readout: April 2027 · NCT05090371 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Divozilimab's landscape · Ofatumumab's landscape